Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05874635 · ClinicalTrials.gov registry record · NA
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
A NA study of Diabetes Mellitus, Type 2 and Insulin Resistance, sponsored by Signos.
- Active
- Registry status
- NA
- Development phase
- 20,000
- Enrollment target
- 1
- Study location
NCT05874635: Active NA study of Diabetes Mellitus, Type 2 and Insulin Resistance, sponsored by Signos.
NCT05874635 is a NA study of Diabetes Mellitus, Type 2 and Insulin Resistance that is active but no longer recruiting, run by Signos. The registered enrollment target is 20,000 participants, above the 4,428-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (352% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05874635, a NA study of Diabetes Mellitus, Type 2 and Insulin Resistance, is active but no longer recruiting, sponsored by Signos.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.
Primary Outcome
Glucose measured in mg/dl
Conditions Studied
Interventions
- DEVICE Continuous Glucose Monitor Device
Study Locations (1)
California
- Signos - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2029-05-10 |
| Phase | NA |
What the registry record for NCT05874635 still lists
NCT05874635 is an interventional study that assigns participants to a tested intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 4,428-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (352% higher).
The record links to 7 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitor Device is the first listed.
NCT05874635 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05874635 about?
NCT05874635 is a clinical study titled "Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)". The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in...
What is the current status of trial NCT05874635?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20,000 participants. The study started on 2023-05-11. Estimated completion is 2029-05-10.
What conditions does trial NCT05874635 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Weight Loss, Metabolic Syndrome, Glucose Intolerance.
What interventions are being tested in trial NCT05874635?
The interventions under investigation include: Continuous Glucose Monitor Device (DEVICE).
Who is sponsoring clinical trial NCT05874635?
This trial is sponsored by Signos, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05874635 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05874635's enrollment target sits among peer trials
20,000 8th of 348 higher than 341 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI